A number of studies have revealed that the differential expression and/or activation of myosin II, MLCK, Rho GTPases, and ROCK, commonly indicate enhanced actomyosin contractility and promotes cancer progression across a variety of solid tumors [13,34,35]. This evidence concerns the gene MYLK and cancer.